83 results
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
7 Aug 18
Ocular Therapeutix™ Reports Second Quarter 2018 Financial Results and Business Update
4:06pm
extension study that will be included as part of the current pivotal program. This study will provide additional long-term safety data with repeat … payable, net of discount, current
Total current liabilities
Deferred rent, long-term
Notes payable, net of discount, long-term
Total liabilities
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
7 Nov 18
Ocular Therapeutix™ Reports Third Quarter 2018 Financial Results and Business Update
4:08pm
additional long-term safety data with repeat administration of OTX-TP.
· Enrollment in the Phase 1 clinical trial of OTX-TIC (travoprost implant … current liabilities
Deferred rent, long-term
Notes payable, net of discount, long-term
Total liabilities
Commitments and contingencies (Note 10
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
7 Mar 19
Ocular Therapeutix™ Reports Fourth Quarter and Year End 2018 Financial Results and Business Update
4:06pm
an open-label, one-year safety extension study with OTX-TP. This study is designed to provide additional long-term safety data with repeat … rent, long-term
Notes payable, net of discount, long-term
Total liabilities
Commitments and contingencies
Stockholders’ equity:
Preferred stock
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
3 Mar 20
Results of Operations and Financial Condition
8:50am
fluid in some subjects. The Company plans to continue long-term evaluation of the first two cohorts. This Phase 1 clinical trial is not powered … macular degeneration. We look forward to following these patients to assess the long-term durability of the response. The safety and biological
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
29 Aug 14
Ocular Therapeutix Announces Second Quarter 2014 Financial Results
12:00am
Deferred revenue
Notes payable, net of discount, current
Total current liabilities
Preferred stock warrants
Deferred rent, long-term
Notes payable, net … of discount, long-term
Total liabilities
Commitments and contingencies
Redeemable convertible preferred stock (Series A, B, C, D and D-1), $0.001 par
8-K
EX-99.1
vrn9bq3l6vhzxmtf
8 May 18
Ocular Therapeutix™ Reports First Quarter 2018 Financial Results and Business Update
4:04pm
8-K
zt8kmpxaf 9rx9k
7 Feb 20
Other Events
8:18am
8-K
EX-99.1
5534t2seih qij27c
13 Apr 20
Ocular Therapeutix™ Provides Business Update and Response to COVID-19 Global Pandemic
8:05am
8-K
EX-99.1
t8s87j6bu
12 Mar 20
Ocular Therapeutix™ Reports Fourth Quarter and Year End 2019 Financial Results and Business Update
4:03pm
8-K
EX-99.1
dbn fk5ay
20 Jan 21
Regulation FD Disclosure
8:04am
8-K
EX-99.2
3g8b40e
3 Mar 20
Results of Operations and Financial Condition
8:50am
PRE 14A
dg516o u0cbgzoz
13 Apr 21
Preliminary proxy
5:07pm
8-K
EX-99.1
9n3ee2t6t r3
10 May 19
Ocular Therapeutix™ Reports First Quarter 2019 Financial Results and Business Update
7:38am
8-K
EX-99.1
zmmzm 3hlaz830zq
7 Nov 22
Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update
4:04pm
8-K
EX-99.1
ik4fsv9fa107i30q
5 Nov 20
Ocular Therapeutix™ Reports Third Quarter 2020 Financial Results and Business Update
4:11pm